Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: A literature review

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue 1, 2008, Pages 19-31

  Dalainas, Ilias ^a  

^a 492 General Military Hospital   (Greece)

Author keywords

Bleeding; Disseminated intravascular coagulation; Fibrin; Multi organ failure; Scoring system; Tissue factor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; DALTEPARIN; FIBRIN DEGRADATION PRODUCT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; RECOMBINANT HIRUDIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

ADENOCARCINOMA; AMNION FLUID EMBOLISM; ANTIINFLAMMATORY ACTIVITY; AORTA ANEURYSM; BLEEDING; BURN; CLINICAL FEATURE; CLINICAL TRIAL; CRYOPRECIPITATE; DIAGNOSTIC ACCURACY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FAT EMBOLISM; FETUS DEATH; FIBRINOLYSIS; GLOMERULITIS; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; INTRAVASCULAR HEMOLYSIS; KASABACH MERRITT SYNDROME; LABORATORY TEST; MEDLINE; MULTIPLE TRAUMA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PREECLAMPSIA; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOLUTIO PLACENTAE; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE;

ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; HIRUDIN THERAPY; HUMANS;

EID: 41149125428     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. LEVI M, TEN CATE H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
2. LANDOIS. Transfusion des Blutes. Leipzig, 1875.
3. TEN CATE H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28: S9-S11.
4. LEVI M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191-2195.
5. DE JONGE E, LEVI M, STOUTENBEEK CP, VAN DEVENTER SJH. Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998; 55: 767-777.
6. WADA H. Disseminated intravascular coagulation. Clin Chim Acta 2004; 344:13-21.
7. TEN CATE H, TIMMERMAN JJ, LEVI M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-717.
8. LEVI M, DE JONGE E, VAN DER POLL T, TEN CATE H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
9. WADA H, NAGANO T, TOMEOKU M, KUTO M, KARITANI Y, DEGUCHi K, et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1982; 30: 315-322.
10. THUS LG, DE BOER JP, DE GROOT MCM, HACK CE. Coagulation disorders in septic shock. Intensive Care Med 1993; 19: Suppl 1: S8-S15.
11. BAGUN T. Disseminated intravascular coagulation: diagnosis and treatment. Br Med J 1996; 312: 683-687.
12. GANDO S, KAMEUE T, NANZAKI S, NAKANISHI Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-228.
13. BONE RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154: 26-34.
14. SZLACHETKA DM. Kasabach-Merritt syndrome: a case review. Neonatal Netw 1998; 17: 7-15. [Erratum, Neonatal Netw 1998; 17: 21].
15. ABOULAFIA DM, ABOULAFIA ED. Aortic aneurysm-induced disseminated intravascular coagulation. Ann Vasc Surg 1996; 10: 396-405.
16. KAZMERS A, JACOBS L, PERKINS A, LINDENAUER SM, BATES E. Abdominal aortic aneurysm repair in Veterans Affairs Medical Centers. J Vasc Surg 1996; 23: 191-200.
17. RUGGENENTI P, LUTZ J, REMUZZI G. Pathogenesis and treatment of thrombotic microangiopathy. Kidney Int 1997; 58: S97-S101.
18. VAN DER POLL T, BÜLLER HR, TEN CATE H, WORTEL CH, BAUER KA, VAN DEVENTER SJ, HACK CE, SAUERWEIN HP, ROSENBERG RD, TEN CATE JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
19. LEVI M, VAN DER POLL T, TEN CATE H, VAN DEVENTER SJH. The cytokinemediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 1997; 27: 3-9.
20. BARBUI T, FALANGA A. Disseminated intravascular coagulation in acute leukaemia. Semim Thromb Hemost 2001; 27: 593-604.
21. RICKLES FR, LEVINE MN, EDWARDS RL. Hemostatic alterations in cancer patients. Cancer Met Rev 1992; 11: 237-248.
22. FALANGA A, BARBUI T, RICKLES FR, L.EVINE MN. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993; 70: 343-350.
23. FALANGA A, OFOSU FA, DELAINI F, OLDANI E, DEWAR L, LUI L, BARBUI I, The hypercoagulable state in cancer: Evidence for impaired thrombin inhibition. Blood Coagul Fibrinolysis 1994; 5: S19-S23.
24. FALANGA A. Mechanisms for hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28(Suppl 3): 50-60.
25. TALLMAN MS, KWAAN HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-553.
26. BAUER KA, ROSENBERG RD. Thrombin generation in acute promyelocytic leukaemia. Blood 1984; 64: 791-796.
27. BOOTH NA, BENNETT B. Plasmin-alpha-2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. Br J Haematol 1984; 56: 545-556.
28. REDDY VB, KOWAL-VERN A, HOPPENSTEADT DA, KUMAR A, WALENGA JM, FAREED J, SCHUMACHER HR. Global and hemostatic markers in acute myeloid leukemia. Am J Clin Pathol 1990; 94: 397-403.
29. SPEISER W, PABINGER-FASCHING I, KYRLE PA, KAPIOTIS S, KOTTAS-HELDENBERG A, BETTELHEIM P, LECHNER K. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: Activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut 1990; 61: 298-302.
30. GANDO S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001; 27: 585-592.
31. LEVI M, TEN CATE H, VAN DER POLL T, VAN DEVENTER SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979.
32. GANDO S, NANZAKI S, MORIMOTO Y, ISHITANI T, KEMMOTSU O. Tissue factor pathway inhibitor response does not correlate with tissue-factor induced DIC and MODS in trauma patients. Crit Care Med 2001; 24: 262-266.
33. GANDO S. Serial studies of protein C in trauma patients. Jpn J Thromb Hemost 1996; 7: 312-318.
34. OWINGS JT, GOSSELIN R. Acquired antithrombin deficiency following severe traumatic injury: Rationale for study of antithrombin supplementation. Semin Thromb Hemost 1997; 23(Suppl 1): 17-24.
35. DE JONGE E, VAN DER POLL T, KESECIOGLU J, LEVI M. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. Semin Thromb Hemost 2001; 27: 667-674.
36. RAO LV, NORDFANG O, HOANG AD, PENDURTHI UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129.
37. MAMMEN EF. Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
38. BOLLER HR, TEN CATE JW. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989; 87: 44S-48S.
39. SEITZ R, WOLF M, EGBRING R, HAVEMANN K. The disturbance of hemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989; 43: 22-28.
40. FOURRIER F, CHOPIN C, GOUDEMAND J, HENDRYCX S, CARON C, RIME A, MAREY A, LESTAVEL P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
41. BLAUHUT B, KRAMAR H, VINAZZER H, BERGMANN H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985; 39: 81-89.
42. VINAZZER H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 1989; 15: 347-352.
43. FOURRIER F, CHOPIN C, HUART JJ, RUNGE I, CARON C, GOUDEMAND J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
44. BAUDO F, CAIMI TM, DE CATALDO F, RAVIZZA A, ARLATI S, CASELLA G, CARUGO D, PALARETI G, LEGNANI C, RIDOLFI L, ROSSI R, D'ANGELO A, CRIPPA L, GIUDICI D, GALLIOLI G, WOLFLER A, CALORI G. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled doubleblind, randomized, multicenter study. Intens Care Med 1998; 24: 336-342.
45. EISELE B, LAMY M, THUS LG, KEINECKE HO, SCHUSTER HP, MATTHIAS FR, FOURRIER F, HEINRICHS H, DELVOS U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intens Care Med 1998; 24: 663-672.
46. INTHORN D, HOFFMANN JN, HARTL WH, MUHLBAYER D, JOCHUM M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10: 90-96.
47. INTHORN D, HOFFMANN JN, HARTL WH, MUHLBAYER D, JOCHUM M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8: 328-334.
48. MAKI M, TERAO T, IKENOUE T, TAKEMURA T, SEKIBA K, SHIRAKAWA K, SOMA H. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial. Gynecol Obstet Invest 1987; 23: 230-240.
49. NAWROTH PP, HANDLEY DA, ESMON CT, STERN DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464.
50. NAWROTH PP, STERN DM. Modulation of enclothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
51. FUKUDOME K, ESMON CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491.
52. BOEHME MW, DENG Y, RAETH U, BIERHAUS A, ZIEGLER R, STREMMEL W, NAWROTH PP. Release of thrombomodulin from endothelial cells by concerted action of TNFalpha and neutrophils: In vivo and in vitro studies. Immunology 1996; 87:134-140.
53. SLUNGAARD A, VERCELLOTTI GM, TRAN T, GLEICH GJ, KEY NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993; 91: 1721-1730.
54. HESSELVIK JF, MALM J, DAHLBACK B, BLOMBACK M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65: 126-129.
55. BERNARD GR, VINCENT JL, LATERRE PF LAROSA SP, DHAINAUT JF, LOPEZ-RODRIGUEZ A, STEINGRUB JS, GARBER GE, HELTERBRAND JD, ELY EW, FISHER CJ Jr. Recombinant human Protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
56. ØSTERUD B, BJØRKID E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001; 27: 605-617.
57. CAMERER E, KOLSTO AB, PRYDZ H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
58. MANN KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-174.
59. MORRISSEY JH, FAKHRAI H, EDGINGTON TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50: 129-135.
60. CREASEY AA. New potential therapeutic modalities: Tissue factor pathway inhibitor. Sepsis 1999; 3: 173-182.
61. DE JONGE E, DEKKERS PE, CRFASEY AA, HACK CE, PAULSON SK, KARIM A, KESECIOGLU J, LEVI M, VAN DEVENTER SJ, VAN DER POLL T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
62. KEMME MJ, BURGGRAAF J, SCHOEMAKER RC, PAULSON S, KARIM A, LENTJES EG, CHILDS A, BRAECKMAN RA, CHEN AF. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther 2000; 67: 504-511.
63. ESMON CT. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000; 95: 1113-1116.
64. CREASEY AA, CHANG AC, FEIGEN L, WÜN TC, TAYLOR FB JR, HINSHAW LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860.
65. TAYLOR FBJ, EMERSON TEJ, JORDAN R, CHANG AK, BUCK, KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circulatory Shock 1988; 26: 227-235.
66. TAYLOR FB, CHANG A, ESMON CT, D'ANGELO A, ViGANO-D'ANGELO S, BLICK KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
67. COALSON JJ, BENJAMIN B, ARCHER LT, BELLER B, GILLIAM CL, TAYLOR FB, HINSHAW LB. Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circulatory Shock 1978; 5: 423-437.
68. TAYLOR FBJ, CHANG AC, PEER GTet al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-368.
69. CUNNINGHAM MA, ROMAS P, HUTCHINSON P, HOLDSWORTH SR, TIPPING PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94: 3413-3420.
70. LEVI M, TEN CATE H, BAUER KA, VAN DER POLL T, EDGINGTON TS, BÜLLER HR, VAN DEVENTER SJ, HACK CE, TEN CATE JW, ROSENBERG RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
71. SUFFREDINI AF, HARPEL PC, PARRILLO JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172.
72. GANDO S, NAKANISHI Y, TEDO I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23: 1835-1842.
73. NOSSEL HL. Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165-167.
74. HACK EC. Fibrilolysis in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 633-638.
75. KARIO K, MATSUO T, KODAMA K, MATSUO M, YAMAMOTO K, KOBAYASHI H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis 1992; 22: 179-186.
76. TAKAHASHI H, TATEWAKI W, WADA K, HANANO M, SHIBATA A. Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders [see comments]. Am J Hematol 1990; 33: 90-95.
77. OKAMOTO K, TAKAKI A, TAKEDA S, KATOH H, OHSATO K. Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: Determination of prothrombin fragment 1 + 2 and other markers. Haemostasis 1992; 22: 17-24.
78. ASAKUPA H, JOKAJI H, SAITO M, UOTANI C, KUMABASHIRI I, MORISHITA E, YAMAZAKI M, AOSHIMA K, MATSUDA T. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrin 1994; 5: 829-832.
79. NIESSEN RW, LAMPING RJ, JANSEN PM, PRINS MH, PETERS M, TAYLOR FB JR, DE VULDER JJ, TEN CATE JW, HACK CE, STURK A. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78:1088-1092.
80. MESTERS RM, FLORKE N, OSTERMANN H, KIENAST J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75: 902-907.
81. PRALONG G, CALANDRA T, GLAUSER MP, SCHELLEKENS J, VERHOEF J, BACHMANN F, KRUITHOF EK. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462.
82. BRANDTZAEG P, JOO GB, BRUSLETTO B, KIERULF P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-278.
83. HORAN JT, FRANCIS CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 657-666.
84. YU M, NARDELLA A, LECHET L. Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit Care Med 2000; 28: 1777-1780.
85. OKAJIMA K, UCHIBA M, MURAKAMI K, OKABE H, TAKATSUM K. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 186-191.
86. CARR JM, MCKINNEY M, MCDONAGH J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol 1989; 91: 280-287.
87. BICK RL, BAKER WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thromb Res 1992; 65: 785-790.
88. WADA H, WAKITA Y, NAKASE T, SHIMURA M, HIYOYAMA K, NAGAYA S, DEGUCHI H, MORI Y, KANEKO T, DEGUCHI K, FUJII J, SHIKU H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 255-260.
89. LANE DA, IRELAND H, KNIGHT I, WOLFF S, KYLE P, CURTIS JR. The significance of fibrinogen derivatives in plasma in human renal failure. Br J Haematol 1984; 56: 251-260.
90. VANDEWATER L, CARR JM, ARONSON D, MCDONAGH J. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood 1986; 67: 1468-1473.
91. MARDER VJ, FEINSTEIN D, FRANCIS C, COLMAN RW. Consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman E, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott; 1994: pp. 1023-1063.
92. LEVI M, DE JONGE E, VAN DER POLL, TEN GATE H. Advantages in the understanding of the pathogenic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hem 2001; 27: 569-575.
93. COLMAN RW, RUBIN RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990; 17: 172-186.
94. SARRIS AH, KEMPIN S, BERMAN E, MICHAELI J, LITTLE C, ANDREEFF M, GEE T, STRAUS D, GANSBACHER B, FILIPPA D. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79: 1305-1310.
95. GIBNEY EJ, BOUCHIER-HAYES D. Coagulopathy and abdominal aortic aneurysm. Eur J Vasc Surg 1990; 4: 557-562.
96. EL-DESSOUKY M, AZMY AF, RAINE PA, YOUNG DG. Kasabach-Merritt syndrome. J Pediatr Surg 1988; 23: 109-111.
97. D'AMICO JA, HOFFMAN GC, DYMENT PG. Klippel-Trenaunay syndrome associated with chronic disseminated intravascular coagulation and massive osteolysis. Cleve Clin Q 1977; 44: 181-188.
98. POON MC, KLOIBER R, BIRDSELL DC. Epsilonaminocaproic acid in the reversal of consumptive coagulopathy with platelet sequestration in a vascular malformation of Klippel-Trenaunay syndrome. Am J Med 1989; 87: 211-213.
99. ALPERT LI, BENISCH B. Hemangioendothelioma of the liver associated with microangiopathic hemolytic anemia. Report of four cases. Am J Med 1970; 48: 624-628.
100. BICK RL. Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation. A new clinical syndrome. Ann N Y Acad Sci 1981; 370: 851-854.
101. DE BOER K, TEN CATE JW, STURK A, BORM JJ, TREFFERS PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100.
102. WEINER CP. Preeclampsia-eclampsia syndrome and coagulation. Clin Perinatol 1991; 18: 713-726.
103. WEINER CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol 1986; 13: 705-717.
104. MCDOUGALL RJ, DUKE GJ. Amniotic fluid embolism syndrome. Case report and review. Anaesth Intens Care 1995; 23: 735-740.
105. TAYLOR JR FB, TOH CH, HOOTS WK, WADA H, LEVI M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - on behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001; 86: 1327-1230.
106. LEVI M, DE JONGE E, MEIJERS J. The diagnosis of disseminated intravascular coagulation. Blood Rev 2002; 16: 217-223.
107. HOCK TOH C. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 653-656.
108. MINAMIKAWA K, WADA H, WAKITA Y, OHIWA M, TANIGAWA M, DEGUCHI K, HIRAOKA N, HUZIOKA H, NISHIOKA J, HAYASHI T. Increased activated protein C- protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost 1994; 71: 192-194.
109. DOWNEY C, KAZMI R, TOH CH. Novel and diagnostically applicable information from optical wave-form analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98: 68-73.
110. TOH CH, DOWNEY C, DWYRE L. Thromboplastin sensitivity in waveform analysis. Thromb Haemost 2000; 84: 517-518.
111. DOWNEY C, KAZMI R, TOH CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998; 80: 65-69.
112. KOBAYASHI N, MAEKAWA T, TAKAPA M, TANAKA H, GONMORI H. Criteria for diagnosis of DIC based on analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983; 49: 265-275.
113. FEINSTEIN DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988; 14: 351-362.
114. LITTLE JR. Purpura fulminans treated successfully with anticoagulation: report of a case. JAMA 1959; 169: 36-40.
115. GASKINS JR RA, DALLDORF FG. Experimental meningococcal septicemia: effect of heparin therapy. Arch Pathol Lab Med 1976; 100: 318-324.
116. CORRIGAN JR JJ, KIERNAT JF. Effect of heparin in experimental Gram-negative septicemia. J Infect Dis 1975; 131: 138-43.
117. CORRIGAN JJ JR. Heparin therapy in bacterial septicemia. J Pediatr 1977; 91: 695-700.
118. FEINSTEIN DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60: 284-287.
119. TAKAHASHI Y, HOSAYA Y, IMAOA K, ADACHI T, NIINA H, WATANABE M, MOCHIZUKI H. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin. Thromb Haemost 1997; 77: 789-795.
120. AUDIBERT G, LAMBERT H, TOULEMONDE F, ALEXANDRE P, LAPREVOTE-HEULLY MC, BOLLAERT PE, BAUER P, LARCAN A. Utilisation d'une héparine de bas poids moléculaire, la CY 222, dans le traitement des coagulopathies de consommation. J Mal Vasc 1987; 12 Suppl. B: 147-151.
121. GILLIS S, DANN EJ, ELDOR A. Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. Eur J Haematol 1995; 54: 59-60.
122. SAKURAGAWA N, HASEGAWA H, MAKI M, NAKAGAWA M, NAKASHIMA M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter cooperative double-blind trial in comparison with heparin. Thromb Res 1993; 72: 475-500.
123. FREUND M, CAZENAVE JP, COURTNEY M, DEGRYSE E, ROITSCH C, BERNAT A, DELEBASSÉE D, DEFREYN G, MAFFRAND JP. Inhibition by recombinant hirudins of experimental venous thrombosis and dissemilated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 1990; 63: 187-192.
124. ZAWILSKA K, ZOZULINSKA M, TUROWIECKA Z, BLAHUT M, DR0BNIK L, VINAZZER H. The effect of along-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993; 69: 3153-3120.
125. DICKNEITE G, CZECH J. Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis. Thromb Haemost 1994; 71: 768-772.
126. KESSLER CM, TANG Z, JACOBS HM, SZYMANSKI LM. The suprapharmacological dosing of antithrombin concentrate for Staphylococcus aureus induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997; 89: 4393-401.
127. DE PONT AC, BAKHTIARI K, HUTTEN BA, DE JONGE E, VROOM MB, MEIJERS JC, BÜLLER HR, LEVI M. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis: A case control study. Crit Care 2005; 9: R490-R497.
128. ABRAHAM E, LATERRE PF, GARG R, LEVY H, TALWAR D, TRZASKOMA BL, FRANÇOIS B, GUY JS, BROCKMANN M, REA-NETO A, ROSSAINT R, PERROTIN D, SABLOTZKI A, ARKINS N, LITTERBACK BG, MACIAS WL; ADMINISTRATION OF DROTRECOGIN ALFA (ACTIVATED) IN EARLY STAGE SEVERE SEPSIS (ADDRESS) STUDY GROUP. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341.
129. ELSAYYED YA, NAKAGAWA K, KAMIKUBO YI, ENJYOJI KI, KATO H, SUEISHI K. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol 1996; 106: 574-583.
130. ABRAHAM E, REINHART K, SVOBODA P, SEIBERT A, OLTHOFF D, DAL NOGARE A POSTIER R, HEMPELMANN G, BUTLER T, MARTIN E, ZWINGELSTEIN C, PERCELL S, SHU V, LEIGHTON A, CREASEY AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-2089.
131. ABRAHAM E, REINHART K, OPAL S, DEMEYER I, DOIG C, RODRIGUEZ AL, BEALE R, SVOBODA P, LATERRE PF, SIMON S, LIGHT B, SPAPEN H, STONE J, SEIBERT A, PECKELSEN C, DE DEYNE C, POSTIER R, PETTILÄ V, ARTIGAS A, PERCELL SR, SHU V ZWINGELSTEIN C, TOBIAS J, POOLE L, STOLZENBACH JC, CREASEY AA; OPTIMIST TRIAL STUDY GROUP. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-247.